Integrated BioPharma Inc. (OTCMKTS:INBP – Get Free Report) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 4,700 shares, a decline of 30.9% from the September 30th total of 6,800 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 17,000 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 17,000 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the company’s shares are sold short.
Integrated BioPharma Trading Down 1.7%
Integrated BioPharma stock traded down $0.01 during trading hours on Monday, hitting $0.30. The company had a trading volume of 11,250 shares, compared to its average volume of 17,898. The firm has a market cap of $9.29 million, a P/E ratio of 15.01 and a beta of 0.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.21 and a current ratio of 4.42. Integrated BioPharma has a 1 year low of $0.22 and a 1 year high of $0.42. The company has a 50-day moving average price of $0.29 and a two-hundred day moving average price of $0.30.
Integrated BioPharma (OTCMKTS:INBP – Get Free Report) last released its quarterly earnings data on Tuesday, September 23rd. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $14.18 million during the quarter. Integrated BioPharma had a net margin of 1.49% and a return on equity of 4.04%.
Integrated BioPharma Company Profile
Integrated BioPharma, Inc, together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
Featured Articles
- Five stocks we like better than Integrated BioPharma
- Options Trading – Understanding Strike Price
- $134M in Insider Moves: What It Might Mean for KMI, ISRG and QS
- How to start investing in penny stocks
- 3 Stocks Flashing Buy Signals With $8.5 Billion in Buybacks
- What Investors Need to Know to Beat the Market
- Freshpet Insiders Called the Bottom: Now It’s Time to Buy
Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
